Tetrandrine

汉防己甲素

Report date: 2024/06/26 12:00:52
NMEFirst In Class

Base Information

Drug NameTetrandrine
Drug Alias Name粉防己碱汉防己硷汉防己碱FF-0019NSC-77037 +[6] 
ClassificationNatural product/ExtractSmall molecules > Heterocyclic drugs
Mechanisms of ActionCatenin beta 1 inhibitorsCalcium/calmodulin-dependent protein kinase type II subunit gamma inhibitors
TargetsCatenin beta 1Calcium/calmodulin-dependent protein kinase type II subunit gamma
Therapy Area/IndicationsMyelodysplastic SyndromesSilicosisLung Neoplasms +[5] 
Global Approved IndicationsSilicosisLung Neoplasms
Approved Indications in ChinaSilicosisLung Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2015/05/19
Country/TerritoryUnited StatesNew ZealandAustralia +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEscend Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAustralasian Leukaemia & Lymphoma GroupEscend Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesSilicosisLung Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XX
Related LinksWikipediaKEGG